Orchard Therapeutics clinical trials

Acquired by Kyowa Kirin Co., Ltd., Jan 24, 2024 · source ↗

The registry lists 5 studies whose lead sponsor is Orchard Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 16, 2026.

Before and after it joined Kyowa Kirin Co., Ltd.

First submitted before Orchard Therapeutics became part of Kyowa Kirin Co., Ltd.: 5
First submitted after Orchard Therapeutics became part of Kyowa Kirin Co., Ltd.: 0
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Active, not recruiting: 3
Completed: 2

Phase

Phase 2: 3
Phase 1: 2
Phase 3: 2

Where

Italy: 5
Netherlands: 1
United States: 1
United Kingdom: 1

Registry sponsor names on this page

Orchard Therapeutics5 studies

Something wrong with this grouping? Tell us on the Kyowa Kirin Co., Ltd. page.

Studies

Recruiting first, then most recently updated. Showing 5 of 5. All Kyowa Kirin Co., Ltd. studies →

Gene Therapy With Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients With Mucopolysaccharidosis Type I, Hurler VariantActive, not recruitingNCT03488394Phase 1/2
Sponsor listed in the registry: Orchard Therapeutics · First submitted before Orchard Therapeutics became part of Kyowa Kirin Co., Ltd.
A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)CompletedNCT03392987Phase 2
Sponsor listed in the registry: Orchard Therapeutics · First submitted before Orchard Therapeutics became part of Kyowa Kirin Co., Ltd.
A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCTActive, not recruitingNCT06149403Phase 3
Sponsor listed in the registry: Orchard Therapeutics · First submitted before Orchard Therapeutics became part of Kyowa Kirin Co., Ltd.
Gene Therapy for Metachromatic Leukodystrophy (MLD)CompletedNCT01560182Phase 1/2
Sponsor listed in the registry: Orchard Therapeutics · First submitted before Orchard Therapeutics became part of Kyowa Kirin Co., Ltd.
OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)Active, not recruitingNCT04283227Phase 3
Sponsor listed in the registry: Orchard Therapeutics · First submitted before Orchard Therapeutics became part of Kyowa Kirin Co., Ltd.